Exelixis Inc Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Exelixis Inc (EXEL) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $7.53 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-10
- Exelixis Inc unrecognized tax benefits, increase resulting from current period tax positions for the quarter ending 2018-03-30 was $1.08M.
- Exelixis Inc unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2026 was $7.53M, a 45.39% decline from fiscal 2025.
- Exelixis Inc unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $13.80M, a 57.07% decline from fiscal 2023.
- Exelixis Inc unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $32.14M, a 678.32% increase from fiscal 2022.
- Exelixis Inc unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $4.13M, a 86.41% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 3 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 9 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|---|---|
| 2026-01-02 | $7.53M 10-K · filed 2026-02-10 | ||
| 2025-01-03 | $13.80M 10-K · filed 2026-02-10 | ||
| 2023-12-29 | $32.14M 10-K · filed 2026-02-10 | ||
| 2022-12-30 | $4.13M 10-K · filed 2025-02-11 | ||
| 2021-12-31 | $2.21M 10-K · filed 2024-02-06 | ||
| 2021-01-01 | $3.31M 10-K · filed 2023-02-07 | ||
| 2020-01-03 | $2.43M 10-K · filed 2022-02-18 | ||
| 2018-12-28 | $1.08M 10-K · filed 2021-02-11 | ||
| 2018-03-30 | $1.08M 10-K · filed 2020-02-25 | ||
| 2017-12-29 | $17.38M 10-K · filed 2019-02-22 | ||
| 2017-09-30 | $17.38M 10-K · filed 2020-02-25 | ||
| 2016-12-31 | $2.30M 10-K · filed 2017-02-27 | ||
| 2016-12-30 | $2.30M 10-K · filed 2019-02-22 | ||
| 2016-01-01 | $8.73M 10-K · filed 2018-02-26 | ||
| 2015-12-31 | $8.73M 10-K · filed 2017-02-27 | ||
| 2014-12-31 | $2.71M 10-K · filed 2017-02-27 | ||
| 2013-12-31 | $7.89M 10-K · filed 2016-02-29 | ||
| 2012-12-31 | $2.09M 10-K · filed 2015-03-02 | ||
| 2011-12-31 | $2.71M 10-K · filed 2014-02-20 | ||
| 2010-12-31 | $3.74M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |